Introduction
============

Lung adenocarcinoma is a common type of lung cancer with high incidence (40%) ([@b1-ol-0-0-7790]). It has high risk of distant metastasis, which poses a severe threat to the survival rates of patients ([@b2-ol-0-0-7790]). However, prognosis varies considerably at different stages of this disease ([@b3-ol-0-0-7790]). Therefore, an effective screening tool is imperative and of critical importance in the clinical management of lung adenocarcinoma, which provides early and accurate detection thereof.

DNA methylation markers are effective biomarkers and promising candidates in the diagnosis of disease ([@b4-ol-0-0-7790],[@b5-ol-0-0-7790]). Aberrant methylation in cancer usually occurs at CpG islands, which results in changes in the transcription of tumor suppressor genes ([@b6-ol-0-0-7790]). For lung adenocarcinoma, several *in vitro* studies have shown the difference of the DNA methylation level between patients and normal controls. For example, *F2RL3* methylation has been demonstrated to be a strong predictor for the incidence of lung adenocarcinoma ([@b7-ol-0-0-7790]). The *p16* gene promoter methylation is also associated with smoking-induced lung adenocarcinoma ([@b7-ol-0-0-7790]). Tomizawa *et al* ([@b8-ol-0-0-7790]) suggested that RASSF1A methylation was significantly associated with pleural involvement, vascular invasion and decreased patient survival time, which may be a powerful marker for the prognosis of patients with lung adenocarcinoma at an early stage. Previous findings have shown the role of DNA methylation in a potential diagnosis of lung adenocarcinoma. However, the pathogenesis involved in lung adenocarcinoma has not been clearly understood.

In the present study, microarray data (GSE66386) were downloaded and a comprehensive bioinformatics approach was performed to screen differentially expressed methylation genes in lung adenocarcinoma samples compared with normal controls. The aim was to identify potential DNA methylation biomarkers and to determine the possible pathogenesis for lung adenocarcinoma.

Materials and methods
=====================

### Microarray data and preprocessing

The gene expression dataset (GSE66386) was collected from the Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/geo/>) database. The dataset included 183 samples, of which 164 were lung adenocarcinoma samples, and 19 were matched normal lung tissue samples. The dataset was uploaded by Bjaanæs *et al* and cited in their study ([@b9-ol-0-0-7790]). The platform of this microarray was Illumina Infinium 450 K Human Methylation BeadChip. The differentially methylated genes were identified using the limma package available at <http://www.bioconductor.org-packages/release/bioc/html/limma.html>. As a result, the DNA methylation data with 456947 CpGs were used for analysis. For preprocessing of the row data, the following probes were removed: i) The distance value (from CpG to SNP) \<2; ii) the minor allele frequency \<0.05; iii) the cross-hybridising probes and sex chromosome-specific DNA probes.

### Identification of genes with methylation differences

The percentage methylation values were expressed as β values. The differential methylation of CpGs between lung adenocarcinoma and control samples were identified if the absolute mean difference between the two groups was \<0.05, and the P-value was \<0.05. Consequently, the P-value was calculated by t-test.

### Functional enrichment analysis of differential methylation of genes

Gene ontology (GO) analysis for screening of differential methylation of genes was conducted to search the vital functions related to the differential gene methylation in lung adenocarcinoma ([@b10-ol-0-0-7790]). The P-values was adjusted into false discovery rate (FDR) by Benjaminiand Hochberg study ([@b11-ol-0-0-7790]). FDR \<0.01 was considered as the cutoff value. The proteins of annotated differential gene methylation were compared with their homologous proteins based on COG database (<http://www.ncbi.nlm.nih.gov/COG>). P-value \<0.05 was regarded as the cut off threshold value. By this strategy, the screened genes with methylation differences were then assigned to different gene functions including cellular component (CC), molecular function (MF) and biological process (BP).

### Pathway analysis

A Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway ([@b12-ol-0-0-7790]) analysis was performed to evaluate the associations between different proteins in the regulation of cell function and metabolism. Fisher\'s test was used to identify significant pathways that were enriched by genes with methylation differences with the threshold of FDR \<0.05.

Results
=======

### Identification of methylation genes

After standardized pretreatment, we collected 413043 CpGs for the subsequent analysis. After further screening, 112662 differentially methylated regions (DMRs) in lung adenocarcinoma patients compared with normal controls, including 57235 upmethylated CpGs and 55427 downmethylated ones. These CpGs were involved in 16,705 genes. The results are summarized as volcano plots ([Fig. 1](#f1-ol-0-0-7790){ref-type="fig"}). The difference of the differentially methylated genes between lung adenocarcinoma and normal control is shown on the x-axis, and the negative P-value was shown on the y-axis.

To obtain more important methylation genes, we initially removed 109 CpGs with β value ≤0.2 or ≥0.8, and then excluded 99954 CpGs with an absolute value of difference between the average β values of the two groups ≥0.2. As a result, 12599 CpGs related to 5,489 genes were obtained.

### Functional enrichment analysis

The 'skeletal system development' function, including 230 significant genes with methylation differences, was identified as the most significant (P=9.46E-27) GO term with 5,489 methylation genes ([Table I](#tI-ol-0-0-7790){ref-type="table"} and [Fig. 2](#f2-ol-0-0-7790){ref-type="fig"}). In addition, embryonic organ morphogenesis (P=8.67E-24), embryonic organ development (P=1.20E-23), and cell fate commitment (P=5.90E-23) were found to be involved in the lung adenocarcinoma.

The function of upmethylated and downmethylated gene sets were compared in this study ([Table II](#tII-ol-0-0-7790){ref-type="table"} and [Fig. 3](#f3-ol-0-0-7790){ref-type="fig"}). Results showed that 2,539 upmethylated genes were enriched in the following pathways: transcription factor activity (P=4.13E-19), RNA polymerase II core promoter proximal region sequence-specific binding (P=1.82E-17), and transcriptional activator activity (P=4.43E-13). A total of 1,600 differential downmethylated genes were mainly enriched in voltage-gated ion channel activity (P=1.13E-09), voltage-gated channel activity (P=1.13E-09) and cation channel activity (P=2.66E-09).

### Pathway analysis

Pathway analysis was used to evaluate the possible pathway associated with lung adenocarcinoma induced by DNA methylation ([Table III](#tIII-ol-0-0-7790){ref-type="table"}). The results showed that significant genes with methylation differences were involved in 74 pathways, among which, the cancer pathways (P=3.64E-07), Rap1 signaling pathway (P=9.21E-05) and calcium signaling pathway (P=9.21E-05) were the important pathways associated with lung adenocarcinoma.

Discussion
==========

Alterations of epigenetics such as DNA methylation are of great importance in carcinogenesis. Increased knowledge has shown the great importance of DNA methylation in lung cancer ([@b13-ol-0-0-7790]). Thus it is of great importance to evaluate the connection between the level of methylation and the increased expression in epigenetic diagnosis and therapy. In the present study, we identified a great amount of genomic regions that showed different methylations in tumor and normal lung adenocarcinoma tissues by microarray based on the methylation screening approach. A total of 12599 DMRs associated with 5,489 genes were eventually screened, including *PTPRF*, *HOXD3*, *HOXD13* and *CACNA1A*. These genes are promising in the development of biomarkers for diagnostic or therapy purposes.

*PTPRF* gene is a member of the protein tyrosine phosphatase (PTP) family, which is known to be a signaling molecule involved in the regulation of cell processes ([@b14-ol-0-0-7790]). It was previously reported to be expressed as a potential predictive marker for treatment with erlotinib in non-small-cell lung cancer ([@b15-ol-0-0-7790]), and has been found to promote cell migration in several types of cancer ([@b16-ol-0-0-7790],[@b17-ol-0-0-7790]). The present study showed that the methylated *PTPRF* was focused on the role of regulation of protein binding. In lung adenocarcinomas, *CRBP-1* high expression was suggested to be an aggressive phenotype ([@b18-ol-0-0-7790]). *CPBP-1* is known as a 15 kDa cytosolic binding protein that is crucial in retinol uptake and esterification ([@b19-ol-0-0-7790],[@b20-ol-0-0-7790]). *CPBP-1* was also highly expressed in lung adenocarcinoma ([@b18-ol-0-0-7790]), and played an important role in protein binding. Therefore, we consider that the function of methylated *PTPRF* associated with protein binding is of great importance in lung adenocarcinomas.

Homeobox (*HOX*) genes, belonging to the homeobox family, are important in the regulation of transcription which controls the expression of morphogenesis-related genes ([@b21-ol-0-0-7790]) In the present study, *HOXD3* was upmethylated in lung adenocarcinoma patients compared to the normal controls. In addition, *HOXD3* was involved in two possible functions associated with lung adenocarcinoma, positive regulation of cell development and cell-substrate adhesion. In an *in vitro* experiment, Hamada *et al* ([@b22-ol-0-0-7790]) have shown that the overexpression of *HOXD3* gene significantly promoted migration and invasion in human lung cancer A549 cells. Authors of that study suggested that *HOXD3* overexpression prominently induced a high expression of integrin β3, which promotes pulmonary metastasis via increased endothelium and adhesion ([@b22-ol-0-0-7790]). Another study identified that in A549 cells, overexpressing *HOXD3* gene accelerated the expression of N-cadherin and integrins ([@b23-ol-0-0-7790]). These results suggest that the aberrant methylation of *HOXD3* plays an important role in the regulation of genes involved in the metastasis and invasion of lung adenocarcinoma via the function of cell-substrate adhesion.

Another *HOX* gene, *HOXD13*, was screened with differential hypermethylation enriched in the transcriptional activator activity in lung adenocarcinoma in the present study. Hypermethylated *HOXD13* has been reported in malignant melanomas ([@b24-ol-0-0-7790]), breast cancer ([@b25-ol-0-0-7790]) and extrahepatic cholangiocarcinoma ([@b26-ol-0-0-7790]), with methylation rates of 30.8, 94.38 and 57.7%, respectively. Thus, the upmethylation of *HOXD13* is a potential diagnostic biomarker and therapeutic target.

There is insufficient information regarding the relationship between *CACNA1A* and cancer. However, we found that *CACNA1A* was downmethylated in patients with lung adenocarcinoma compared to normal controls. As a novel possible tumor-methylated candidate involved in lung cancer, the *CACNA1A* methylation has been identified from microarray experiment ([@b27-ol-0-0-7790],[@b28-ol-0-0-7790]). However, the methylated level as well as its possible carcinogenic mechanism have not been clearly understood. Further analysis in the present study showed that downmethylated *CACNA1A* was involved in several functions such as the calcium channel and was also voltage-dependent. The intracellular calcium overload is regarded as an important factor inducing mitochondrial-dependent apoptosis directly and indirectly ([@b29-ol-0-0-7790]). The function of mitochondrial transmembrane potential may be interrupted by calcium phosphate in the matrix ([@b30-ol-0-0-7790]). In a previous study, it was shown that in TCM, curcumin exerted an anti-proliferative effect by calcium overload via activating the calcium channel in lung cancer cells ([@b31-ol-0-0-7790]). Therefore, downmethylated *CACNA1A* may be involved in the development of lung adenocarcinoma via the calcium channel signaling pathway.

In conclusion, from the DNA methylation profiling, we achieved two purposes: i) identification of DNA methylation changes that may be associated with lung adenocarcinoma. ii) Identification of function and pathway of methylated genes that may be involved in lung adenocarcinomas. From these data, we concluded that screened genes with methylation differences, including *PTPRF*, *HOXD3*, *HOXD13* and *CACNA1A* serve as potential markers and may be used in the diagnosis and therapy of patients with lung adenocarcinoma.
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###### 

The top 10 enriched GO descriptions for differentially expressed methylation genes.

  ID           Description                                             P-value    P-adjust   Count
  ------------ ------------------------------------------------------- ---------- ---------- -------
  GO:0001501   Skeletal system development                             9.46E-27   5.19E-23   230
  GO:0048562   Embryonic organ morphogenesis                           8.67E-24   2.20E-20   150
  GO:0048568   Embryonic organ development                             1.20E-23   2.20E-20   197
  GO:0045165   Cell fate commitment                                    5.90E-23   8.10E-20   133
  GO:0007389   Pattern specification process                           5.27E-21   5.79E-18   199
  GO:0021953   Central nervous system neuron differentiation           1.81E-20   1.66E-17   100
  GO:0007423   Sensory organ development                               1.87E-19   1.47E-16   217
  GO:0048705   Skeletal system morphogenesis                           4.66E-19   3.20E-16   112
  GO:0030900   Forebrain development                                   1.11E-18   6.75E-16   164
  GO:0048667   Cell morphogenesis involved in neuron differentiation   1.79E-18   9.50E-16   213

GO, Gene Ontology.

###### 

The top 5 enriched down- and upmethylated pathways involved in the development of lung adenocarcinoma.

  Cluster          ID           P-value    P-adjust   Count
  ---------------- ------------ ---------- ---------- -------
  Downmethylated   GO:0005244   2.52E-12   1.13E-09   52
  Downmethylated   GO:0022832   2.52E-12   1.13E-09   52
  Downmethylated   GO:0005261   8.86E-12   2.66E-09   69
  Downmethylated   GO:0022843   5.10E-11   1.15E-08   40
  Downmethylated   GO:0004984   2.64E-10   4.00E-08   84
  Upmethylated     GO:0000982   4.19E-22   4.13E-19   124
  Upmethylated     GO:0001228   3.7E-20    1.82E-17   116
  Upmethylated     GO:0001077   1.35E-15   4.43E-13   85
  Upmethylated     GO:0001159   1.92E-13   4.74E-11   113
  Upmethylated     GO:0000987   1.55E-12   3.05E-10   110

GO, Gene Ontology.

###### 

The top 10 enriched pathways involved in development of lung adenocarcinoma.

  ID         Pathway name                                               P-value    P-adjust      Count
  ---------- ---------------------------------------------------------- ---------- ------------- -------
  hsa05200   Pathways in cancer                                         1.28E-09   3.64E-07      152
  hsa04015   Rap1 signaling pathway                                     9.70E-07   9.21E-05      85
  hsa04020   Calcium signaling pathway                                  7.74E-07   9.21E-05      75
  hsa04921   Oxytocin signaling pathway                                 1.78E-06   0.000127156   67
  hsa04024   cAMP signaling pathway                                     2.75E-06   0.000156673   80
  hsa03008   Ribosome biogenesis in eukaryotes                          6.25E-06   0.000296837   5
  hsa04010   MAPK signaling pathway                                     9.25E-06   0.000376788   96
  hsa00190   Oxidative phosphorylation                                  1.08E-05   0.000384468   13
  hsa04550   Signaling pathways regulating pluripotency of stem cells   1.34E-05   0.000423855   59
  hsa04022   cGMP-PKG signaling pathway                                 1.73E-05   0.000448535   54
